High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.
Adam B WeinerChristina Y YuMitali KiniYang LiuElai DavicioniAntonina MitrofanovaTamara L LotanEdward M SchaefferPublished in: Prostate cancer and prostatic diseases (2022)
Markers of plasma cell activity might be leveraged to augment clinical trial targeting and selection and better understand the potential for immune-based treatments in patients with PCa at a high risk of recurrence following local treatment.